New Delhi, Dec. 19 -- Pfizer India and Cipla announced a partnership on Friday in which Cipla will exclusively market and distribute four Pfizer brands in India to increase their reach.

These include cough syrups Corex Dx and Corex LS, non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and oral antibiotic Dalacin C, the companies said in a joint statement. Pfizer will manufacture and supply these medicines to Cipla for India.

This marks the first partnership between Pfizer and Cipla in India. The partnership aims to make Pfizer's medicines widely available across India by combining its portfolio with Cipla's market reach, the companies said in the statement.

Pfizer India's country president Meenak...